These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 11313934)

  • 1. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A.
    Rashid SF; Moore JS; Walker E; Driver PM; Engel J; Edwards CE; Brown G; Uskokovic MR; Campbell MJ
    Oncogene; 2001 Apr; 20(15):1860-72. PubMed ID: 11313934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation.
    Banwell CM; Singh R; Stewart PM; Uskokovic MR; Campbell MJ
    Recent Results Cancer Res; 2003; 164():83-98. PubMed ID: 12899515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
    Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
    Skowronski RJ; Peehl DM; Feldman D
    Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
    Zhuang SH; Burnstein KL
    Endocrinology; 1998 Mar; 139(3):1197-207. PubMed ID: 9492054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells.
    Suenaga M; Soda H; Oka M; Yamaguchi A; Nakatomi K; Shiozawa K; Kawabata S; Kasai T; Yamada Y; Kamihira S; Tei C; Kohno S
    Int J Cancer; 2002 Feb; 97(5):621-5. PubMed ID: 11807787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells.
    Rokhlin OW; Glover RB; Guseva NV; Taghiyev AF; Kohlgraf KG; Cohen MB
    Mol Cancer Res; 2006 Feb; 4(2):113-23. PubMed ID: 16513842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects.
    Campbell MJ; Reddy GS; Koeffler HP
    J Cell Biochem; 1997 Sep; 66(3):413-25. PubMed ID: 9257197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
    Frønsdal K; Saatcioglu F
    Prostate; 2005 Feb; 62(3):299-306. PubMed ID: 15389787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
    Ly LH; Zhao XY; Holloway L; Feldman D
    Endocrinology; 1999 May; 140(5):2071-6. PubMed ID: 10218956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells.
    Banwell CM; MacCartney DP; Guy M; Miles AE; Uskokovic MR; Mansi J; Stewart PM; O'Neill LP; Turner BM; Colston KW; Campbell MJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2004-13. PubMed ID: 16609009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin.
    Campbell MJ; Elstner E; Holden S; Uskokovic M; Koeffler HP
    J Mol Endocrinol; 1997 Aug; 19(1):15-27. PubMed ID: 9278857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic inhibition of prostate cancer cell lines by a 19-nor hexafluoride vitamin D3 analogue and anti-activator protein 1 retinoid.
    Campbell MJ; Park S; Uskokovic MR; Dawson MI; Jong L; Koeffler HP
    Br J Cancer; 1999 Jan; 79(1):101-7. PubMed ID: 10408700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
    Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
    Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells.
    Yee SW; Campbell MJ; Simons C
    J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):228-35. PubMed ID: 16483768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct HDACs regulate the transcriptional response of human cyclin-dependent kinase inhibitor genes to Trichostatin A and 1alpha,25-dihydroxyvitamin D3.
    Malinen M; Saramäki A; Ropponen A; Degenhardt T; Väisänen S; Carlberg C
    Nucleic Acids Res; 2008 Jan; 36(1):121-32. PubMed ID: 17999998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells.
    Huang H; Reed CP; Zhang JS; Shridhar V; Wang L; Smith DI
    Cancer Res; 1999 Jun; 59(12):2981-8. PubMed ID: 10383164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines.
    de Vos S; Holden S; Heber D; Elstner E; Binderup L; Uskokovic M; Rude B; Chen DL; Le J; Cho SK; Koeffler HP
    Prostate; 1997 May; 31(2):77-83. PubMed ID: 9140119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
    Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
    Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
    Walton TJ; Li G; Seth R; McArdle SE; Bishop MC; Rees RC
    Prostate; 2008 Feb; 68(2):210-22. PubMed ID: 18092350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.